<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02163512</url>
  </required_header>
  <id_info>
    <org_study_id>ALB-BET-2011-01</org_study_id>
    <nct_id>NCT02163512</nct_id>
  </id_info>
  <brief_title>Effect of Beta-adrenergic Blockers on Cardiac Function, Systemic and Splanchnic Haemodynamic and Kidney Function in Cirrhotic Patiets With Refractory Ascites</brief_title>
  <acronym>ALB-BET</acronym>
  <official_title>Effect of Beta-adrenergic Blockers on Cardiac Function, Systemic and Splanchnic Haemodynamic and Kidney Function in Cirrhotic Patiets With Refractory Ascites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentric, observational and prospective study with two groups of treatment: Refractory
      ascites and non-refractory ascites. All patients should be prescribed beta-adrenergic
      blockers as primary or secondary profilaxis for variceal bleeding.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac function</measure>
    <time_frame>Baseline and after 4 weeks</time_frame>
    <description>Echocardiography: changes in left ventricular ejection fraction, cardiac output,
Electrocardiography: changes in Qt interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Kidney function</measure>
    <time_frame>Baseline and after 4 weeks</time_frame>
    <description>Echocardiography: Renal vascular Doppler ultrasonographic parameters (resistive index of kidney arteries)
Blood test: serum creatinine, estimated glomerular filtration rate (eGFR) calculated by the Modification of Diet in Renal Disease formula, IL18, KIM1, NGAL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers and vasoactive endogenous system</measure>
    <time_frame>Baseline and after 4 weeks</time_frame>
    <description>Levels of monoaminergic systems: variations in activity of the autonomous nervous system (levels of renin, aldosterone and noradrenaline)
Immune system activation: TNF-alpha, IL 6, TNFR I y II, LBP</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Hepatic Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Non-refractory ascites</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Refractory ascites</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with hepatic cirrhoris and refractory or non-refractory ascites. These patients
        are going to be treated with beta blockers as primary or secondary prophylaxis of variceal
        bleeding
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18-80

          -  Patients previously prescribed with beta-blockers

          -  Any type of hepatic cirrosis that has been diagnosed by clinical, analytic and image
             criteria

          -  Mild to serious ascites. Classification on refractory or non-refractory ascites
             depends on the patient´s response to diuretic treatment. Refractory ascites is defined
             by the Ascites´Board International Criteria as the lack of response, ascites
             recurrency or complications occurrence by diuretic drugs uptake

          -  Esophageal varicose vein in which beta blockers treatment is indicated as primary or
             secondary prophylaxis. Primary prophylaxis is indicated for big esophageal varicose
             veins, small varicose veins with red signs or varicose veins in patients with B-C
             Child-Pugh stage. Secondary prophylaxis is indicated for all those patients that have
             previously presented varicose bleeding.

          -  Patients giving a written consent to participate in the study after having received
             enough information about the design, objectives and risks.

        Exclusion Criteria:

          -  Hepatocellular carcinoma &gt;5 cm

          -  Total portal vein thrombosis or Cavernous transformation of the portal vein

          -  Insuficiencia renal (creatinina sérica &gt;3 mg/dl).

          -  Kidney insufficiency (seric creatinine &gt;3 mg/dl)

          -  Contraindications to beta-blockers: Cardiac or breathing insufficiency,
             auricular-ventricular blocking grade &gt;1.

          -  Anticoagulant treatment

          -  Patients with a intrahepatic portosystemic shunt

          -  Beta-blockers Hypersensitivity

          -  Pregnancy and breastfeeding

          -  Women of childbearing age must commit to undergo an effective contraception during the
             treatment and at least one month after finishing it.

          -  Patients with severe controlled or not controlled psychiatric condition

          -  Patients´ lack of commitment to follow all visits.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Agustin Albillos, M.D</last_name>
    <phone>91 3368085</phone>
    <email>agustin.albillos@uah.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luis Tellez, M.D.</last_name>
    <email>luistevilla@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Bañares</last_name>
    </contact>
    <investigator>
      <last_name>Rafael Bañares, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agustin Albillos, M.D.</last_name>
      <phone>91 3368085</phone>
      <email>agustin.albillos@uah.es</email>
    </contact>
    <investigator>
      <last_name>Agustín Albillos, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>June 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2014</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic cirrhosis</keyword>
  <keyword>Ascites</keyword>
  <keyword>Beta blockers treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic Agents</mesh_term>
    <mesh_term>Adrenergic Antagonists</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

